Concepedia

Adam Vigil

AV

Statistics

Publications

2

Citations

34

H-Index

2

Active since

2022

Affiliations

Intellia Therapeutics (United States)(Current)

AstraZeneca (United Kingdom)

Amgen (United States)

Adam Vigil is an author at Intellia Therapeutics (United States) specializing in allergy, quantitative pharmacology, and drug discovery.

ORCID

Top concepts

Publications per year

2022–2024

2

Publications

2

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs

Scott P. Henry, Cecilia Arfvidsson, Josh Arrington et al. · Nucleic Acid Therapeutics · 2022 · 18 citations

, , +14

2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard <u>(Part 3</u> – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity &amp; Technologies; Biotherapeutics Immunogenicity &amp; Risk Assessment; ADA/NAb Assay/Reporting Harmonization)

Johanna Mora, Rachel Palmer, Leslie Wagner et al. · Bioanalysis · 2024 · 16 citations · Full text

Rows per page

1–2 of 2